 |
 |
 |
| Axiom
edition 7
Spring 2013
Creating the functional pharma organisation
Value Communications v2.0
SafetyGauge
click
here to view |
Axiom
edition 6
Autumn 2011
Engaging e-patients: How to steer pharma
to safety
Value-based pricing in the UK: Developing
an evaluation framework for burden of illness
Improving performance for pharmacovigilance
inspections
click
here to view |
Axiom
edition 5
Spring 2011
Focus on real-world data, including EU
and US stakeholder research
In mint condition, the economic benefits
of maintaining a
healthy workforce
China: access all areas? Reimbursement
opportunities in China
click
here to view |
 |
 |
 |
| Axiom
edition 4
Spring 2010
Focus on Talent management
Implementing patient access schemes in
the UK
How can risk minimisation tools be improved?
An industry perspective
Innovation in patient compliance
Opinion on value demonstration
click
here to view |
Axiom
Digest
2009
A collection of the best articles from
Pope Woodhead's bi-annual newsletter
click
here to view |
Axiom
edition 3
Spring 2009
The who, what, when and how of
local EU payer engagement
Registries: Real-world knowledge for competitive
advantage
Has clinical trial disclosure helped the
average patient?
An industry perspective
Focus on commercial innovation and risk
sharing
click
here to view |
 |
 |
|
| Axiom
edition 2
Spring/Summer 2008
5 steps to an integrated value
proposition
PW’s ‘digital conversation’
risk
minimisation tool
Success factors for managing
key opinion leaders
Industry and payer perspectives
on cost-effectiveness evaluation
click
here to view |
Axiom edition
1
Autumn 2007
Opinion on Risk Management
Discussion of the five phases to
develop a successful mature
product portfolio
Perspective on the markets in
Poland and Spain
click
here to view |
|
| 
|
|
 |
 |
 |
|
China
- Access all areas?
Rebecca Zhang
Wenting Zhang
Chris Easley
Pharmaceutical
Market Europe
October 2012
|
Patient-Reported
Outcomes (PROs) in safety adverse event reporting – a
new framework
Anjan K Banerjee, DM, MBA, Simon Ingate,
PhD,
Stephen Mayall, PhD,
Sally Okun, RN,
David Clifford,
Paul Wicks, PhD
and James Heywood.
Abstract poster from
DIA 2013 |
Behavioural
assessment offers improved evaluation of risk minimisation tools
(RMTs)
Anjan K Banerjee, DM, MBA, Simon Ingate,
PhD, MBA,
Jon Mann,
Steve Hutson, PhD
and Rebecca Zhang, MD, PhD.
Abstract poster from
ICPE 2012 |
 |
 |
 |
|
China:
mapping the territory
Understanding the structure of China's
healthcare reimbursement system is the first step to clearing
the mist and visualising opportunities and challenges.
Pharmaceutical
Market Europe July/August 2012 |
Risk
Evaluation and Mitigation Strategies (REMS)
Detecting risk pre-market, managing risk
post-approval, and the role of US and EU regulators
SCRIP Insights August 2011 |
Toolkit
for patients’ organisations
Collaborative initiative to support groups
in developing effective relationships with
key stakeholders
Pharmaceutical Market Europe September
2011 |
 |
 |
 |
|
Lifestyle
advice and drug therapy post-myocardial infarction: a survey
of UK current practice.
|
Biosimilars:
how to manage risks
PharmacoVigilance Review
Volume 3 Number 4
November 2009
click
here to view |
China:
Access All Areas?
Wenting Zhang and
Chris Easley
click
here to view
|
 |
 |
 |
|
PW
Guide to Services (Chinese)
click
here to view |
Communicating
product
value to local payers is
a new challenge
Pharmaceutical
Marketing Europe
March/April 2009
click here to view |
 |
 |
|
Risk
rationale
Pharma needs a culture of
proactive pharmacovigilance
and risk minimisation
Pharmaceutical
Marketing Europe
July/August 2007
click
here to view
|
Real
Time Post Marketing Evaluation
of Therapeutic Risk Management
Plans(RMPs)
– A Novel Pharmacoepidemiological Tool?
Pharmacoepidemiology and
Drug Safety 2008
click
here to view
|
 |
|
|
Partnering
patients
In this article Dr Beverly Barr
discusses the long-term benefits of pharma engaging with patient
organisations. |
|
